Author

Lixian Jin

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Bristol-Myers Squibb (United States), Novartis (United States), Lishui City People's Hospital, Rutgers Cancer Institute

OpenAlex ID: A5113697930

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

2025 · Thierry André, Elena Elez, et al. · The Lancet · 255

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

2009 · Adam M. Brufsky, Linda D. Bosserman, et al. · Clinical Breast Cancer · 214

Final 5‐year results of Z‐FAST trial

2011 · Adam M. Brufsky, W. Graydon Harker, et al. · Cancer · 193

Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole

2008 · Adam Brufsky, Nigel Bundred, et al. · The Oncologist · 175

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

2024 · Thierry Andre, Elena Elez, et al. · Journal of Clinical Oncology · 63

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study

2019 · André Lacroix, Feng Gu, et al. · Pituitary · 27

PDF

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma

2019 · Xiting Cao, Derek Tang, et al. · Clinical Genitourinary Cancer · 17

A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer

2005 · Susan Goodin, Kamakshi V. Rao, et al. · Cancer Chemotherapy and Pharmacology · 17

Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis

2021 · Huadong Deng, Jianming Lei, et al. · Thoracic Cancer · 15

PDF

2024 · Heinz-Josef Lenz, Sara Lonardi, et al. · Journal of Clinical Oncology · 14

PDF

First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

2025 · Thierry Andre, Elena Elez, et al. · Journal of Clinical Oncology · 9

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.

2024 · Heinz-Josef Lenz, Michael J. Overman, et al. · Journal of Clinical Oncology · 8

PDF

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.

2025 · Heinz-Josef Lenz, Sara Lonardi, et al. · Journal of Clinical Oncology · 6

PDF

2023 · Heinz-Josef Lenz, Michael J. Overman, et al. · Journal of Clinical Oncology · 5

A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors.

2022 · Toni K. Choueiri, Bradley Alexander McGregor, et al. · Journal of Clinical Oncology · 5

Ctim-32. a Parallel Cohort Phase 2 Study of Regorafenib Plus Nivolumab for Recurrent or Metastatic Solid Tumors: Results in Patients With Glioblastoma Multiforme (gbm) or Anaplastic Astrocytoma (aa)

2023 · Matteo Simonelli, Mario Caccese, et al. · Neuro-Oncology · 2

PDF

Ctim-13. Phase 1 Clinical Trial of Oncolytic Viral Immunotherapy With Can-2409 + Valacyclovir in Combination With Nivolumab and Standard of Care (soc) in Newly Diagnosed High-grade Glioma (hgg)

2021 · Patrick Wen, Laura Aguilar, et al. · Neuro-Oncology · 2

PDF

Phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203).

2026 · Tiago Biachi de Castria, Ian Chau, et al. · Journal of Clinical Oncology · 1

Clinical utility of the Idylla CDx MSI test in identifying MSI-H mCRC patients eligible for nivolumab monotherapy or in combination with ipilimumab therapy (CheckMate 8HW phase III trial).

2026 · Thierry Andre, Sara Lonardi, et al. · Journal of Clinical Oncology · 1

PDF

Assessment of the Value of Nivolumab Plus Ipilimumab for Treating Microsatellite Instability-High/Mismatch Repair Deficiency Metastatic Colorectal Cancer: Indirect Treatment Comparison and Cost-Effectiveness Analysis

2026 · Lytske J. Bakker, Katharina Nickel, et al. · Advances in Therapy

PDF

Nivolumab + ipilimumab (NIVO + IPI) vs NIVO in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC): CheckMate 8HW subgroup analyses including treatment-free status and outcomes in long-term survivors.

2026 · Elena Elez, Thierry Andre, et al. · Journal of Clinical Oncology

Association of progression-free survival (PFS) with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) status determined by single vs dual validated companion diagnostic (CDx) assays: CheckMate-8HW post hoc analyses.

2026 · Thierry Andre, Sara Lonardi, et al. · Journal of Clinical Oncology

Abstract CT136: Interim safety and efficacy results from a phase 1b study of CM24 in combination with nivolumab in adults with advanced solid tumors

2022 · Erkut Borazanci, Mohammed Najeeb Al Hallak, et al. · Cancer Research

Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.

2019 · Xiting Cao, Derek Tang, et al. · Journal of Clinical Oncology

Works count: 24

Citation count: 1,027

H-index: 10

I10-index: 10